TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protara Therapeutics Inc (TARA) is not a strong buy for a beginner, long-term investor at this time. While analysts have a positive outlook with high price targets, the stock lacks immediate positive catalysts, has weak financial performance, and shows no significant trading signals or trends. The technical indicators are neutral, and options data reflects low trading sentiment. Given the investor's impatience and preference for long-term gains, it is better to hold off on investing in TARA until stronger signals or catalysts emerge.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 41.051, and moving averages are converging, showing no clear trend. Key support is at 5.016, and resistance is at 5.44. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
Analysts have initiated coverage with Overweight ratings and high price targets ($24-$27), citing the potential of TARA-002 in addressing unmet medical needs. The company is advancing in clinical trials with de-risked opportunities.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Financials show negative net income and declining EPS. Technical indicators and options data reflect low trading sentiment. The stock has a 30% chance of minor losses in the next day.
In Q4 2025, revenue remained at 0, showing no growth. Net income improved by 35.54% YoY but remains negative at -$17.31M. EPS dropped by -19.15% YoY to -0.38, reflecting continued financial struggles.
Analysts from JPMorgan and Piper Sandler have initiated Overweight ratings with price targets of $24 and $27, citing the company's clinical-stage biotech opportunities and the potential of TARA-002 as a de-risked product.
